Summary
70 / 100 · Bulios Score
What speaks for it
- Earnings per share grew by 116% a year over the last 3 years.
- The share price is below the Bulios Fair Price.
- Out of every 100 USD of revenue, 11 USD is left as net profit.
What to watch
- Revenue growth is slowing: 4.9% a year over the last 3 years against 16% over 5 years.
- It earns only 2.0 USD a year on every 100 USD of invested capital.
- It missed profit estimates 4 times in the last 8 quarters.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 10.6 USD for 1 USD of yearly profit. Over the last five years it was 71.3 USD on average.
Valuation in detailIs it growing?
Yes, fastRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 16% a year over 5 years. Over the last 3 years it grew by 4.9% a year. For the next fiscal year analysts expect revenue to grow by 4.5%. Earnings per share grew by 116% a year over the last 3 years.
Growth in detailDoes it make money?
Very wellWhere 100 USD of revenue goes
- Cost of sales 53 USD
- Sales and administration 37 USD
- Taxes and other -0.8 USD
- Net profit 11 USD
Net profit, industry median (Drug Manufacturers - Specialty & Generic) 10 USD
Out of every 100 USD of revenue, 11 USD is left as net profit.
Profitability in detailIs it financially healthy?
YesRepaying all its debt would take 2.8 years of free cash flow. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 5
- Hold 0
- Sell 0
Today's price within the analysts' price targets
The average target of $18 is 182% above today's price. 100% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Retail Segment 55%
- Consumer Packaged Goods Segment 45%
By region
The company reports no revenue by region.
Retail Segment brings in 55% of revenue. Consumer Packaged Goods Segment grew fastest, by 9.7% a year.
Segments in detail